Lund, Sweden and Dallas, TX – November 7, 2016—Dignitana AB, a world leader
in
medical scalp-cooling technology, announced today that the DigniCap®
scalp
cooling system, which was cleared in December 2015 by the FDA to
effectively
reduce the likelihood of chemotherapy-induced hair loss in women
with breast
cancer, will soon be available in 13 additional medical centers in
the United
States.

The DigniCap® system is the first and only scalp cooling
device to complete
rigorous FDA clinical trials in America, where seven out of
ten patients with
early-stage breast cancer kept at least 50% of their
hair.

Demand for the FDA-cleared DigniCap® system continues to be strong, with
orders
for 22 additional units coming in this week. The orders represent
contracts with
three healthcare providers and will be placed in 13 medical
centers across four
states. This means that DigniCap® is now contracted for 53
medical centers
across 17 U.S. states in its first year of production.

“We’re
very excited by this growth and expansion in the U.S., which is fueled
by
patient and physician demand,” says William Cronin, Chief Operating Officer
of
Dignitana, Inc., the US subsidiary of Dignitana AB. “In line with our goals
for
2016, we are pleased to be able to make this quality of life option
available
for as many patients across the US as possible.”

The DigniCap® scalp
cooling system features a patented tight-fitting silicone
cooling cap that is
placed directly on the head, and an outer neoprene cap that
insulates and
secures the silicone cap. The cooling cap is connected to a
cooling and control
unit with touch screen prompts. A liquid coolant circulates
throughout the
silicone cap, delivering consistent and controlled cooling to all
areas of the
scalp. The cap is fitted to the head, and the temperature of the
scalp is
lowered, resulting in vasoconstriction with reduced delivery of
chemotherapy to
the scalp, as well as reduced cellular uptake of drugs due to
decreased intra
follicular metabolic rate. These factors together reduce the
risk of
chemotherapy-induced hair loss.

Media Contacts:

USA
         Sweden

Caren
Browning
Semmy Rülf

King +
Company
                                     Chairman of the board, Dignitana
AB

00 1 212 561-7464
0046 (0)709
312730

Caren.Browning@kingcompr.com
semmy.rulf@gmail.com



The information in
this press release is such that Dignitana AB must disclose it
in accordance
with the EU market abuse regulation. The information was
submitted, by the
above contact, for publication at 17.00 (CET), November 7,
2016.
About
Dignitana
Dignitana AB is a Swedish public company, based in Lund, and
manufacturer of the
medical cooling device DigniCap®. Dignitana AB is listed on
the OMX Nasdaq First
North stock exchange and has appointed Erik Penser
Bankaktiebolag as Certified
Advisor. Headquartered in Dallas, Texas,
Dignitana, Inc. is the U.S.
subsidiary of Dignitana AB. For more information
visit www.dignitana.com.

 About the scalp cooling system DigniCap®
Dignitana’s
core product - DigniCap® - is a patented scalp-cooling system that
offers
cancer patients the ability to keep their hair during chemotherapy.
DigniCap®
is developed to provide continuous cooling with high efficacy, safety
and
acceptable patient comfort.